Stephanie Arnio, OD
Optometrist · Augusta, MENPI 1205363470
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Lumenis BE Inc accounts for 67.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $2,431 and has fallen 84.7% since, to $372 in 2025. Among optometrist clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $69.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$2K
- Alcon$330
- AbbVie$205
- Sun Pharmaceutical Industries Inc.$134
- Bausch & Lomb Americas Inc.$105
- Novartis$85
- plus $230 from 6 others
What the payments were for
- Food & beverage$3,350100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 1 | $2,261 |
| Alcon | 6 | $330 |
| AbbVie(2 entities) | 10 | $205 |
| Sun Pharmaceutical Industries Inc. | 8 | $134 |
| Bausch & Lomb Americas Inc. | 5 | $105 |
| Novartis | 5 | $85 |
| Coopervision Inc. | 5 | $79 |
| Aerie Pharmaceuticals, Inc. | 3 | $57 |
| Tarsus Pharmaceuticals, Inc. | 2 | $37 |
| Biotissue Holdings Inc. | 1 | $24 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Dompe US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,350 in reported general payments places this provider in the 95th percentile of 224 optometrist providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 49 | $60,968 |
| XiidraLifitegrast | 53 | $44,094 |
| LumiganBimatoprost | 47 | $34,659 |
| XdemvyLotilaner | 11 | $20,349 |
| MieboPerfluorohexyloctane/Pf | 18 | $17,343 |
| CequaCyclosporine | 13 | $15,340 |
| VyzultaLatanoprostene Bunod | 14 | $9,987 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $8,939 |
| Cyclosporine | 19 | $3,343 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $2,802 |
| Fluorometholone | 32 | $2,428 |
| Latanoprost | 84 | $1,051 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 34 | $513 |
| Brimonidine Tartrate | 25 | $427 |
| Prednisolone Acetate | 14 | $403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $205 | $95,62796 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $105 | $71,42585 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $37 | $20,34911 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $134 | $15,34013 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $57 | $8,93913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 224 optometrist providers in Maine.
Other optometrist in Augusta
- Adam PuiiaAugusta$2K
- Peter KembleAugusta$2K
- Jillian JanesAugusta$2K
- James BrewerAugusta$1K
- Michelle HigginsYarmouth$31K
- Katherine HillPortland$7K
- Renee WhelanFalmouth$6K
- Jacqueline WillsGorham$4K
- Steven GoldsteinPortland$4K
- Andre AchenbachBrunswick$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.